Synonyms: RTA 408 | RTA-408 | Skyclarys®
omaveloxolone is an approved drug (FDA (2023), EMA (2024))
Compound class:
Synthetic organic
Comment: Chemically omaveloxolone (RTA 408) is a second generation synthetic oleanane triterpenoid compound, which structurally resembles bardoxolone, and has difluoropropanamide replacing the carboxylic acid moiety.
This compound is claimed in patent WO2013163344A1. The chemical structure represented above, was drawn from this patent, but structures with alternate stereochemistry are submitted in PubChem. Pharmacologically omaveloxolone activates the Nrf2 transcription factor, to modulate expression of proteins that have antioxidative, anti-inflammatory, and mitochondrial bioenergetic activities [6-7]. |
|
Immunopharmacology Comments |
Omaveloxolone activates the cytoprotective transcription factor Nrf2 and inhibits NF-κB signaling. This action reduces oxidative stress and inflammation. |